Latest News and Events
Filter by
Selections
July 14, 2021
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Read MoreJuly 6, 2021
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Read MoreJune 30, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
Read MoreJune 26, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
Read MoreJune 25, 2021
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
Read MoreJune 23, 2021
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Read MoreJune 21, 2021